ABSTRACT
] i responses to hypoxia in isolated PAs (43).
One possible explanation for these findings is that hypoxia caused release of Ca Recently, we reported that several so-called "canonical transient receptor potential (TRPC)" proteins were expressed in smooth muscle of distal PAs (60), which are thought to be the major vascular locus of HPV (49). These proteins are homologs of TRP and ] i do not necessarily translate to changes in pulmonary vascular resistance. In the present study, therefore, we assessed the contribution of SOCCs and CCE to HPV in isolated lungs, where physiologically relevant pulmonary vasomotor responses can be measured directly.
METHODS

Isolated Lung Preparation
Male Wistar rats (200-400 g) were anesthetized with sodium pentobarbital (65 mg/kg IP). A tracheostomy was performed and the animal was ventilated with room air at a tidal volume of 10 ml/kg and rate of 30 min -1 (Harvard Rodent Ventilator Model 883;
Harvard Apparatus Co., Holliston, MA). A thoracotomy was performed, heparin (100 U) injected into the right ventricular cavity, and the animal exsanguinated from the femoral artery. The ventilating gas was changed to 16%O 2 -5%CO 2 . Cannulae were inserted into the main PA and left atrium, which drained into a heated reservoir. The lungs were perfused with a peristaltic pump (Ismatec Reglo Analog Pump; Cole Parmer, Inc., Vernon Hills, IL) at 40 ml/kg/min with Krebs Ringer Bicarbonate solution (KRBS) containing (in mM) 118 NaCl, 4.7 KCl, 0.57 MgSO 4 , 1.18 KH 2 PO 4 , 25 NaHCO 3 , and 10 glucose. Ficoll (4 g/dL) and sodium meclofenamate (3.1 µM) were added to provide oncotic pressure and prevent release of vasodilator prostaglandins. After flushing the vasculature free of residual blood, the perfusate was recirculated. Lungs treated with LaCl 3 were perfused with bicarbonate-and phosphate-free HEPES-buffered salt solution (HBSS) to prevent precipitation of the antagonist (43, 51, 60), and ventilated without CO 2 . HBSS contained (in mM) 130 NaCl, 5 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 10 HEPES, and 10 glucose, as well as Ficoll (4 g/dL) and sodium meclofenamate (3.1 µM). To mitigate edema formation caused by high perfusion pressures, lungs exposed to KCl were perfused with a 70:30 mixture of KRBS or HBSS and the animal's own blood. Perfusate temperature was monitored with a thermistor in the left atrial effluent and maintained at 37 °C with a heat exchanger. Pulmonary arterial, left atrial, and tracheal pressures were measured at end-expiration relative to the bottom of the lung with pressure transducers (Model P10EZ; Spectramed, Inc., Oxnard, CA) and recorded with a computer linked recording system (Powerlab; ADInstruments, Colorado Springs, CO). End-expiratory tracheal and left atrial pressures were maintained at 3-4 and <0 mmHg, respectively.
Since perfusate flow was also constant, increases in Ppa were assumed to result from pulmonary vasoconstriction. The CCE antagonists, SKF96365 (5, 16, or 50 µM; n = 3, 4, and 5, respectively), NiCl 2 (100, 200, or 500 µM; n = 3, 4, and 5, respectively), and LaCl 3 (1, 10, 30, or 100 µM; n = 6, 6, 4, and 3, respectively) were added to perfusate after the second hypoxic exposure.
Experimental Protocols
Prevention of Pressor Responses to
Additional lungs were exposed similarly to the L-type VOCC antagonist, nifedipine (0.05, 0.5, or 5 µM; n = 4, 3, and 3, respectively), or Ca 2+ -free KRBS perfusate containing 1 mM EGTA (n = 4). Untreated lungs perfused with KRBS (n = 10) or HBSS (n = 6) served as controls.
Reversal of HPV.
After the 20-minute normoxic stabilization period, lungs were exposed to Ang II (0.05 µg bolus injected into main PA) and hypoxia (ventilation with 2% O 2 for 5 min). After 10 min of normoxic recovery, lungs were then ventilated with 2% O 2 for 45 minutes. To assess the ability of CCE antagonists to reverse established HPV, SKF96365 (50 µM; n = 4), NiCl 2 (500 µM; n = 4), or LaCl 3 (10 µM; n = 4) was added to the perfusate during the last 15 min of the 45-min hypoxic exposure. Additional lungs were exposed similarly to nifedipine (5 µM; n = 4) or perfusion with Ca initially by 5 and subsequently by 10 mM increments. After each increment, sufficient time was allowed for Ppa to stabilize. KCl was administered in this manner until Ppa achieved a maximum or the lungs developed edema, as indicated by sudden loss of reservoir volume and increases in Ppa and end-inspiratory tracheal pressure. To examine the effects of CCE antagonists on the pressor response to KCl, SKF96365 (50 µM; n = 6), NiCl 2 (500 µM; n = 6), or LaCl 3 (10 µM, n = 4) were administered 10 minutes before KCl. Additional experiments were performed in lungs exposed to nifedipine (5 µM; n = 6) or Ca 2+ -free perfusate (n = 3) in a similar manner. Untreated lungs perfused with KRBS (n = 11) or HBSS (n = 4) served as controls.
Drugs and Materials
Stock solutions of SKF96365 (10 mM) and KCl (4 M) were made up in water and stored at 4 °C for ≤7 days before use. Stock solutions of NiCl 2 (10 mM) and LaCl 3 (1 and 10 mM) were made up in water on the day of the experiment. Nifedipine was dissolved in dimethylsulfoxide to make a 30 mM stock solution and stored at -4 °C until use. All agents were obtained from Sigma Chemical Co., St. Louis, MO.
Statistical Analysis
Data are expressed as means and SD. Statistical analysis was performed using Students t-test or analysis of variance. If a significant interaction F-ratio was obtained with the latter, pairwise comparison of individual means was performed by calculating the least significant difference. Comparison of group means with control were performed using Dunnett's test. Differences were considered significant when P<0.05. Inhibition by SKF96365 and nifedipine was greatest during Exposure 3, whereas inhibition by NiCl 2 was greatest during Exposure 4. When all concentrations were included in the analysis of variance, LaCl 3 had no effect at 1, 10, and 30 µM and potentiated vasoconstriction at 100 µM. When only those concentrations that did not alter baseline Ppa were included (1 and 10 µM; Fig. 2B and C), LaCl 3 inhibited HPV by 31% at 10 µM, but did not affect the response to Ang II (Fig. 4) .
RESULTS
Prevention of Pressor Responses to Hypoxia and Angiotensin II
The relations between antagonist concentration and pressor response, expressed as a percentage of that measured in control lungs, are shown in Fig 5B). Nifedipine was a potent inhibitor of both responses, but was more effective against hypoxia (IC 50 = 0.034 vs. 0.96 µM). IC 50 for LaCl 3 could not be determined because of the variable effects of this agent (Fig. 4) .
Reversal of HPV
In KRBS-perfused control lungs exposed to hypoxia for 45 min (Fig. 6A and B In HBSS-perfused lungs, 10 µM LaCl 3 , which inhibited initial HPV by 31% (Fig. 4) , did not alter sustained HPV; i.e., minimum ΔPpa between 30 and 45 min, expressed as a percentage of ΔPpa at 30 min, averaged 60.1 (SD 33.8) % in control lungs and 79.1 (SD 25.3) % in lungs treated with 10 µM LaCl 3 (P = 0.382).
Prevention of Pressor Responses to KCl
In KRBS-perfused control lungs, increases in perfusate [KCl] caused progressive increases in Ppa from 10.7 (SD 1.3) mmHg at 5 mM to 34.7 (SD 9.9) mmHg at 40 mM, the highest concentration achieved by all lungs in this group (Fig. 7A and B) . The same maximum [KCl] was achieved by all lungs treated with SKF96365 (50 µM) or NiCl 2 (500 µM). Neither agent altered the Ppa-[KCl] relation (Fig. 6B) . 10 µM LaCl 3 , which caused some prevention of HPV (Fig. 4) , did not prevent vasoconstriction to KCl (Fig.   7C ). In contrast, nifedipine (5 µM) or Ca 2+ -free perfusate almost abolished vasoconstrictor responses to KCl and allowed all lungs to achieve maximum KCl concentrations of 80 and 70 mM, respectively ( Fig. 7A and B) . Fig. 1 and 3-6 ). The antagonist concentrations required for these effects also blocked CCE and hypoxia-induced increases in [Ca 2+ ] i and CCE in rat distal PASMCs (60, 61), but did not block [Ca 2+ ] i responses to KCl in PASMCs (60) or pressor responses to KCl in isolated lungs (Fig. 7) , indicating inhibition of SOCCs but not VOCCs. These results suggest that HPV required CCE in PASMCs.
The validity of this suggestion depends on the specificity of the antagonists.
Inhibition of HPV by SKF96365 (50 µM) and NiCl 2 (500 µM) did not result from nonspecific alterations of baseline vasomotor tone or toxic effects on contractile machinery because baseline Ppa (Fig. 2) and pressor responses to KCl (Fig. 7 ) in lungs exposed to these antagonists were not different from those in control lungs. Their lack of effect on KCl-induced vasoconstriction also indicates that SKF96365 and NiCl 2 did not inhibit VOCCs, confirming previous results in PASMCs (60). Although structurally dissimilar, SKF96365 and NiCl 2 clearly shared the intended action in rat distal PASMCs, where IC 50 s against CCE were estimated to equal 6.3 and 191 µM, respectively (60).
These values were within ranges of potency previously reported for inhibition of CCE in pulmonary arterial and other smooth muscles (10, 14, 15, 19, 29, 34, 43, 56, 64, 68) . pumps at the plasma membrane (5, 48). They also suggest that effects of LaCl 3 on HPV could be the nonspecific result of increased baseline tone. At 10 µM, however, LaCl 3 altered neither baseline tone (Fig. 2C) nor the pressor response to KCl (Fig. 7C ), but inhibited HPV by 31% (Fig. 4) . Since IC 50 for LaCl 3 against CCE in distal PASMCs was 40.4 µM (60), these results are consistent with the hypothesis that HPV requires CCE. At 100 µM, however, LaCl 3 increased baseline tone (Fig. 2B and C) and potentiated HPV (Fig. 3) . Since 100 µM (Fig. 3 and 5) . Indeed, IC 50 for SKF96365 and NiCl 2 against Ang II (24 and 173 µM, respectively) were almost identical to IC 50 against hypoxia (19 and 173, respectively). Nifedipine was less potent against Ang II than HPV (IC 50 = 0.96 and 0.034 µM, respectively), perhaps reflecting a greater contribution of SR Ca 2+ release to the Ang II response due to the short duration of stimulation with Ang II, which was delivered as a bolus into the main PA.
In isolated PAs, the response to hypoxia of more than 30 min duration was usually biphasic, consisting of early transient contraction followed by late sustained contraction (4, 9, 23, 24). Similar temporal characteristics have been described for HPV in isolated lungs (65-67). Because the mechanisms responsible for the early and late phases of HPV might be different (55), we determined whether Ca influx. We cannot explain this discrepancy.
Our conclusion that HPV requires both CCE and voltage-gated Ca
2+
influx is based on our observations that 50 µM SKF96365 and 500 µM NiCl 2 (which blocked CCE but not responses to KCl) or 5 µM nifedipine (which blocked responses to KCl but not CCE) were all quite effective at preventing and reversing HPV (Fig. 1, 3 More investigation is needed to evaluate these possibilities. Mean data for untreated and LaCl 3 -treated rat lungs perfused with HBSS are shown in C.
10 µM LaCl 3 did not alter the KCl response. 
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